Clinical Trials
The clinical trials of Olusium represent a groundbreaking endeavor in the field of healthcare and life sciences. Olusium, a cutting-edge pharmaceutical compound, is poised to revolutionize the way we approach health and well-being. These meticulously designed clinical trials aim to unlock the full potential of Olusium, offering new hope for patients and advancing our understanding of its impact on human health.
Growing Healthcare Impact: Clinical Trials
Our clinical trials are producing high-quality data for healthcare decision making and helping us to continue to redefine stroke care. They aid us in the evaluation of stroke interventions and disease treatment safety and efficacy.See trial details below: including Objective, Status, design, endpoint, and more
MIMD Breast Cancer Morphological Characteristic Analysis
Objective
The primary Objective of the clinical trial is to employ the MIMD protocol to analyze and discern the differentiation pattern between breast cancer samples and healthy samples. This cutting-edge protocol combines advanced multi-omics data analysis techniques with state-of-the-art machine learning algorithms to uncover intricate molecular signatures that can distinguish between cancerous and non-cancerous breast tissues.
Study Plan
Through this clinical trial, we aim to achieve several specific goals:
Identification of Biomarkers.
Understanding Disease Mechanisms.
Enhancing Diagnostic Accuracy.
Tailoring Treatment Approaches.
Contribution to Precision Medicine.
Status
Ongoing
The "Selection of Samples" for this study involved a meticulous process of gathering age-related healthy and breast cancer samples, each meticulously paired with comprehensive Clinical Research Forms (CRF) reports. These reports provide invaluable data on patient demographics, medical history, and other essential information. The careful selection of these samples, along with their corresponding CRF reports, ensures the study's robustness and accuracy. By comparing and contrasting these well-documented samples, our research aims to unveil critical insights into the differentiation patterns between healthy and breast cancer tissues, ultimately advancing our understanding of this complex disease and contributing to improved diagnostic and therapeutic approaches.
Placebo-controlled, age-matched, randomized, unblinded/ double-blinded.
3 Years
MIMD Lung Cancer Morphological Characteristic Analysis
Objective
The primary Objective of the clinical trial is to employ the MIMD protocol to analyze and discern the differentiation pattern between lung cancer samples and healthy samples. This cutting-edge protocol combines advanced multi-omics data analysis techniques with state-of-the-art machine learning algorithms to uncover intricate molecular signatures that can distinguish between cancerous and non-cancerous breast tissues.
Study Plan
Through this clinical trial, we aim to achieve several specific goals:
Identification of Biomarkers.
Understanding Disease Mechanisms.
Enhancing Diagnostic Accuracy.
Tailoring Treatment Approaches.
Contribution to Precision Medicine.
Status
Ongoing
The "Selection of Samples" for this study involved a meticulous process of gathering age-related healthy and lung cancer samples, each meticulously paired with comprehensive Clinical Research Forms (CRF) reports. These reports provide invaluable data on patient demographics, medical history, and other essential information. The careful selection of these samples, along with their corresponding CRF reports, ensures the study's robustness and accuracy. By comparing and contrasting these well-documented samples, our research aims to unveil critical insights into the differentiation patterns between healthy and breast cancer tissues, ultimately advancing our understanding of this complex disease and contributing to improved diagnostic and therapeutic approaches.
Placebo-controlled, age-matched, randomized, unblinded/ double-blinded.
3 Years
MIMD Larynx Cancer Morphological Characteristic Analysis
Objective
The primary Objective of the clinical trial is to employ the MIMD protocol to analyze and discern the differentiation pattern between larynx cancer samples and healthy samples. This cutting-edge protocol combines advanced multi-omics data analysis techniques with state-of-the-art machine learning algorithms to uncover intricate molecular signatures that can distinguish between cancerous and non-cancerous breast tissues.
Study Plan
Through this clinical trial, we aim to achieve several specific goals:
Identification of Biomarkers.
Understanding Disease Mechanisms.
Enhancing Diagnostic Accuracy.
Tailoring Treatment Approaches.
Contribution to Precision Medicine.
Status
Ongoing
The "Selection of Samples" for this study involved a meticulous process of gathering age-related healthy and larynx cancer samples, each meticulously paired with comprehensive Clinical Research Forms (CRF) reports. These reports provide invaluable data on patient demographics, medical history, and other essential information. The careful selection of these samples, along with their corresponding CRF reports, ensures the study's robustness and accuracy. By comparing and contrasting these well-documented samples, our research aims to unveil critical insights into the differentiation patterns between healthy and breast cancer tissues, ultimately advancing our understanding of this complex disease and contributing to improved diagnostic and therapeutic approaches.
Placebo-controlled, age-matched, randomized, unblinded/ double-blinded.
3 Years